Notice of Intent to Publish Funding Opportunity Announcements for Scaling-up and Maintaining Evidence-based Interventions to Maximize Impact on Cancer (SUMMIT) – Lung Cancer Screening and Tobacco Use Treatment for Cancer Survivors (UG3/UH3 Clinical Trial Required)

NCI intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications to each of two companion RFAs as part of SUMMIT: 1) SUMMIT Lung Cancer Screening (LCS) initiative; and 2) SUMMIT Tobacco Use Treatment (TUT) initiative. Up to three (3) Research Projects are expected to be funded as part of the SUMMIT LCS or TUT initiatives. Each Research Project will advance the science of scale-up and sustainment by testing strategies to increase and sustain the delivery of 1) high-quality guideline concordant LCS among populations at high risk for lung cancer, or 2) TUT services for cancer survivors.

The NOFO is expected to use the UG3/UH3 Exploratory/Developmental Cooperative Agreement activity code with the Clinical Trials Required designation. Awards made under this NOFO will initially support a 2-year maximum, milestone-driven UG3 phase with a possible transition to a 4‑year maximum UH3 phase. During the UG3 phase, scale-up and sustainment strategies will be refined and preparatory activities for the scale-up and sustainment trial will occur. NCI will conduct an administrative review of UG3 milestones. Projects that do not complete UG3 milestones will not be approved to move forward to the UH3 phase. The scale-up and sustainment trial will be conducted during the UH3 phase.

The NOFO is expected to be published in late Summer 2024 with an expected application due date in late Fall 2024. Details of a pre-application webinar will be announced after the publication of the NOFO. This Notice is being provided to allow sufficient time for potential applicants with relevant expertise and insights to consider applying for this NOFO. For more information, view the postings for the LCS initiative and TUT initiative.